Immuron Balance Sheet Health
Financial Health criteria checks 6/6
Immuron has a total shareholder equity of A$17.5M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$19.9M and A$2.4M respectively.
Key information
0%
Debt to equity ratio
AU$0
Debt
Interest coverage ratio | n/a |
Cash | AU$16.42m |
Equity | AU$17.53m |
Total liabilities | AU$2.36m |
Total assets | AU$19.88m |
Recent financial health updates
No updates
Recent updates
Immuron suspends research on COVID-19 program
Aug 19Immuron says proposed trials of antibacterial drug put on clinical hold by FDA
Jul 26Immuron to get European patent for drug composition to treat bacterial infection
Jul 07Immuron inks SARS-CoV-2 research agreement with Monash University, shares +12%
Dec 15Immuron soars 26% on positive vaccine responses in gut mediated pathogens
Nov 11Financial Position Analysis
Short Term Liabilities: IMRN's short term assets (A$18.9M) exceed its short term liabilities (A$2.2M).
Long Term Liabilities: IMRN's short term assets (A$18.9M) exceed its long term liabilities (A$132.3K).
Debt to Equity History and Analysis
Debt Level: IMRN is debt free.
Reducing Debt: IMRN had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMRN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: IMRN has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 5.1% each year.